日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.

L-RNA 适配体 CXCL12 抑制剂联合放射疗法和贝伐单抗治疗新诊断的胶质母细胞瘤:I/II 期 GLORIA 试验的扩展。

Giordano Frank A, Layer Julian P, Turiello Roberta, Friker Lea L, Mirallas Oriol, Pregler Barbara E F, Potthoff Anna-Laura, Zeyen Thomas, Weller Johannes, Sperk Elena, Sahm Katharina, Oster Christoph, Kebir Sied, Hambsch Peter, Schäfer Niklas, Kadzik Sebastian, Renovanz Mirjam, Pietsch Torsten, Bisdas Sotirios, Sepúlveda-Sánchez Juan Manuel, Gómez-Puerto Diego, Vieito Maria, Platten Michael, Gkika Eleni, Grauer Oliver M, Tabatabai Ghazaleh, Schneider Matthias, Glas Martin, Seidel Clemens, Herrlinger Ulrich, Hölzel Michael

Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation.

少突胶质细胞转录因子 2 通过抑制 CXCL10 和 CD8+ T 细胞活化来调控胶质母细胞瘤的免疫逃逸。

Zhang Xinchun, Xue Jinjiang, Zhao Cunyan, Zeng Chenqiuyue, Zhong Jiacheng, Yu Gangfeng, Yang Xi, Ling Yao, Li Dazhen, Yang Jiaxiao, Xiu Yun, Li Hongda, Hong Shiyuan, Qiao Liangjun, Chen Song, Lu Q Richard, Deng Yaqi, Tang Zhaohua, Lu Fanghui

SNRPC promotes chemoresistance in Wilms tumor via the NF-κB-CXCL17 axis regulating M2-Type TAMs infiltration and targeted nanotherapy research.

SNRPC 通过 NF-κB-CXCL17 轴调节 M2 型 TAM 浸润,促进 Wilms 肿瘤的化疗耐药性,并进行靶向纳米治疗研究。

Kong Xiangpan, Lei Li, Jin Liming, Ren Chunnian, Mi Tao, Wang Quan, He Dawei

Stabilization of CXCL12 (SDF-1α) via silk fibroin films enhances stem cell migration/retention and functional recovery after stroke.

通过丝素蛋白膜稳定 CXCL12 (SDF-1α) 可增强中风后干细胞的迁移/保留和功能恢复。

Lekouaghet Amira, Sánchez-Díez Marta, Pérez-Rigueiro José, Rojo Francisco J, Ramírez-Castillejo Carmen, Ruiz-León Yolanda, Panetsos Fivos, Guinea Gustavo V, González-Nieto Daniel

The CXCL10/CXCR3 axis is essential for sustaining immunological dormancy in triple-negative breast cancer.

CXCL10/CXCR3 轴对于维持三阴性乳腺癌的免疫休眠至关重要。

Yilmaz Alev, Haerri Lisa, Granda Mateo Estrella, Coquoz Oriana, Lan Qiang, Rüegg Curzio

FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages.

卵巢癌中 FAK 抑制可释放 omega-3 脂肪酸,从而激活产生 CXCL13 的抗肿瘤驻留腹膜巨噬细胞。

Chen Xiao Lei, Tharp Kevin M, Ojalill Marjaana, Ozmadenci Duygu, Boyer Antonia, Haanen Terrance J 3rd, Lawson Christine, Lee Hyojae J, Xia Marvin, Tahon Elise, Zhang Yichi, Minor Cray, Khan Safir Ullah, Anderson Colin C, Nemkov Travis, Rose Michael, Estrada Monica V, Molinolo Alfredo A, Warren Elias, Penalosa Patrick, Eskander Ramez N, McHale Michael T, Wang Shizhen E, Connolly Denise C, Fisch Kathleen M, Stupack Dwayne G, Schlaepfer David D

Docosahexaenoic Acid Attenuates Visceral Pain by Suppressing Spinal CXCL10/CXCR3/ERK Signaling.

二十二碳六烯酸通过抑制脊髓 CXCL10/CXCR3/ERK 信号传导来减轻内脏疼痛。

Yin Xi, Jiang Anqi, Han Yu, Qu Jianhua, Zhao Jianya, Gong Hao, Luo Xiaorong, Li Xu, Lu Ying

CXCL9 and CXCL10 Induce Expression of Nociceptive Ion Channels in Primary Sensory Neurons in Models of HIV-Associated Distal Sensory Polyneuropathy.

CXCL9 和 CXCL10 诱导 HIV 相关远端感觉多发性神经病模型中初级感觉神经元中伤害性离子通道的表达。

Warfield Rebecca, Robinson Jake A, Baak Stephen, Podgorski Rachel M, Gabor Tara A, Caocci Maurizio, Niu Meng, Miller Andrew D, Fox Howard S, Burdo Tricia H

ACT001 synergizes with temozolomide-based chemoradiotherapy to cure refractory glioblastoma by targeting TNF-CXCL10-CD8(+) T-cell immunity.

ACT001 与替莫唑胺化疗放疗协同作用,通过靶向 TNF-CXCL10-CD8(+) T 细胞免疫来治愈难治性胶质母细胞瘤。

Shu Ya, Ding Ze-Hua, Gao Pan-Pan, An Qi, Wu Li-Qin, Zhang Xin-Ran, Jiang Hai-Feng, Miao Cheng, Peng Mei-Ting, Chen Xiao-Qian, Cai Jun, Liu Feng

Tumor-Associated Macrophage-Derived CXCL1 Promotes Endometrial Cancer Progression Through the CXCR2/NF-κB Pathway.

肿瘤相关巨噬细胞衍生的 CXCL1 通过 CXCR2/NF-κB 通路促进子宫内膜癌进展。

Xia Ruiqi, Qi Dingtian, Ji Boshu, Dai Yisheng, Kong Xianchao